10531573

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l2
SAMPLE SEARCH INITIATED 14:57:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 43 TO ITERATE

100.0% PROCESSED 43 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 467 TO 1253
PROJECTED ANSWERS: 80 TO 560

L3 16 SEA SSS SAM L2

=> s l2 full
FULL SEARCH INITIATED 14:57:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 921 TO ITERATE

100.0% PROCESSED 921 ITERATIONS 260 ANSWERS
SEARCH TIME: 00.00.01

L4 260 SEA SSS FUL L2

=> fil hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.00	173.21

FILE 'HCAPLUS' ENTERED AT 14:57:57 ON 16 MAR 2007

10531573

FILE COVERS 1907 - 16 Mar 2007 VOL 146 ISS 13
FILE LAST UPDATED: 15 Mar 2007 (20070315/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l4
L5 20 L4

=> d ed ibib abs hitstr 1-20

L5 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 19 Jan 2007
ACCESSION NUMBER: 2007:61234 HCAPLUS
DOCUMENT NUMBER: 146:184461
TITLE: Preparation of as azolopyridines as inhibitors of JAK3 janus protein kinase.
INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka; Nakajima, Yutaka; Hatanaka, Keiko; Shirakami, Shohei; Sasaki, Hiroshi; Tanaka, Akira; Takahashi, Fumie; Mukoyoshi, Koichiro; Higashi, Yasuyuki; Okimoto, Akira; Hondo, Takeshi; Sawada, Hitoshi
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: PCT Int. Appl., 260pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007007919	A2	20070118	WO 2006-JP314326	20060713

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-698928P P 20050714
JP 2005-378858 A 20051228
OTHER SOURCE(S): MARPAT 146:184461
GI



I

AB Title compds. [I; R1 = H, (substituted) alkyl, aryl; X = bond, NH, O; R2 = H, substituent; R3, R5 = H, alkyl; R4 = (substituted) cycloalkyl, heterocycloalkyl, alkyl, aryl, heteroaryl; M = (CH2)n; n = 0-4; Y = N, CR7; R7 = H, NO2, cyano, amino, halo, acyl, (substituted) alkyl; R2R3 = NR6CO; R6 = H, (substituted) alkyl; R3R4 = (substituted) alkylene; with provisos], were prepared Thus, Et 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (preparation given) and (1S,2R)-2-methylcyclohexanamine were

L5 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
refluxed with diisopropylethylamine in BuOH in a sealed tube at 160° under microwave irradn. to give Et 4-[methyl[(1S,2R)-2-methylcyclohexyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxylate. The latter inhibited JAK3 by >50% at 10-5 M.
IT 920963-74-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of as azolopyridines as inhibitors of JAK3 janus protein kinase)
RN 920963-74-2 HCAPLUS
CN Imidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one, 3,6-dihydro-1-[(3R)-1-[(2-oxo-1-phenyl-3-pyrrolidinyl)carbonyl]-3-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 05 Jan 2007
ACCESSION NUMBER: 2007:17769 HCAPLUS
DOCUMENT NUMBER: 146:121945
TITLE: Preparation of thienopyridine compounds as inhibitors of VEGF receptor and HGF receptor signaling
INVENTOR(S): Saavedra, Oscar Mario; Claridge, Stephen William; Zhan, Lijie; Raeppel, Franck; Vaisburg, Arkadii; Raeppel, Stephane; Deziel, Robert; Mannion, Michael; Zhou, Nancy Z.; Gaudette, Frederic; Isakovic, Ljubomir; Wahhab, Amal; Granger, Marie-Claude; Bernstein, Naomy
PATENT ASSIGNEE(S): Methylgene, Inc., Can.
SOURCE: U.S. Pat. Appl. Publ., 281pp., which which
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007004675	A1	20070104	US 2006-438133	20060519

PRIORITY APPLN. INFO.: US 2005-683036P P 20050520
US 2005-754902P P 20051229
US 2006-785054P P 20060322
OTHER SOURCE(S): MARPAT 146:121945
GI



I II III

IV

AB The title compds. I or II [D = H, halo, NO2, etc.; A1 = CH2, O, S, NH, etc.; A2 = N or CR (wherein R = H, halo, CN, etc.); A3 = CD or N; Ar = III (A4-A7 = N or CH; with the proviso that no more than two of A4-A7 can be N; R2 = H, halo, trihalomethyl, etc.; q = 0-4); G = B-L-T (B = absent, O, C(O), etc.; L = absent, SO2, alkylene, etc.; T = H, alkyl, alkyl-Q, etc.;

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Q = (un)substituted 5-10 membered ring system); Z = O, S, S(O)0-2, (un)substituted NH; with provisos], useful for inhibiting VEGF receptor signaling and HGF receptor signaling, were prepd. E.g., a multi-step synthesis of IV, starting from Me 3-chloro-3-oxopropanoate with aniline, was given. Compds. I were tested for inhibition of c-Met and VEGF activity. For example, IV showed IC50 of 0.27 μM and of 0.199 μM against c-Met and VEGFR, resp. The invention also provides compns. comprising the compd. I or II alone or in combination with other therapeutic agent, and methods for treating cell proliferative diseases and conditions.
IT 918640-72-9P 918641-16-4P 918641-20-0P
918641-23-3P 918641-24-4P 918641-25-5P
918641-28-8P 918641-29-9P 918641-32-4P
918641-43-7P 918641-65-3P 918641-67-5P
918641-76-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienopyridine compds. as inhibitors of VEGF receptor and HGF receptor signaling)
RN 918640-72-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[4-[[2-(1-ethyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]-3-fluorophenyl]-2-oxo-1-phenyl- (CA INDEX NAME)



RN 918641-16-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-[1-[3-(1-pyrrolidinyl)propyl]-1H-imidazol-4-yl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 918641-20-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-[1-[2-(1-pyrrolidinyl)ethyl]-1H-imidazol-4-yl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 918641-23-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 918641-24-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (CA INDEX NAME)

PAGE 1-A



L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 918641-25-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-1-(2-fluorophenyl)-2-oxo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 918641-28-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[4-[[2-[1-(1-methylethyl)-1H-imidazol-4-yl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 918641-29-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-[1-(1-methylethyl)-1H-imidazol-4-yl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)



RN 918641-32-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-3-methyl-2-oxo-1-phenyl- (CA

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-[4-[[methyl[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]phenyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)



RN 918641-67-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)



RN 918641-76-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-[5-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
INDEX NAME)



RN 918641-43-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]amino]phenyl]-2-oxo-1-phenyl- (CA INDEX NAME)



RN 918641-65-3 HCAPLUS

L5 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L5 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 28 Dec 2006
ACCESSION NUMBER: 2006:1354331 HCAPLUS
DOCUMENT NUMBER: 146:93568
TITLE: MAO-B inhibitors useful for treating obesity
INVENTOR(S): McElroy, John F.; Chorvat, Robert J.; Rajagopalan, Parthasarathi
PATENT ASSIGNEE(S): Jenrin Discovery, USA
SOURCE: PCT Int. Appl., 109pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006138475	A2	20061228	WO 2006-US23337	20060615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-691323P P 20050616
US 2006-798467P P 20060508

OTHER SOURCE(S): MARPAT 146:93568

AB The invention provides a method of treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of a MAO-B inhibitor.

IT 676232-63-6 676232-64-7 676232-65-8
676232-66-9 676232-67-0 676232-68-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAO-B inhibitors useful for treating obesity)

RN 676232-63-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(3-fluorophenyl)methoxy]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676232-64-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 676232-65-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(4-fluorophenyl)methoxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 676232-66-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(4-fluorophenyl)methoxy]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676232-67-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676232-68-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-methyl-2-oxo-1-[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 02 Nov 2006
ACCESSION NUMBER: 2006:1147676 HCAPLUS
DOCUMENT NUMBER: 145:455009
TITLE: Substituted cyclic amide derivatives as protein kinase inhibitors for treating hepatocyte growth factor (HGF)-related diseases
INVENTOR(S): Kim, Tae-Seong; Bauer, David; Bellon, Steven; Boezio, Alessandro; Booker, Shon; Choquette, Deborah; D'Amico, Derin C.; D'Angelo, Noel; Dominguez, Celia; Fellows, Ingrid M.; Germain, Julie; Graceffa, Russell; Harmange, Jean-Christophe; Hirai, Satoko; La, Daniel; Lee, Matthew; Liu, Longbin; Norman, Mark H.; Potashman, Michele; Roveto, Philip; Siegmund, Aaron C.; Xi, Ning; Yang, Kevin
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 281pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006116713	A1	20061102	WO 2006-US16344	20060427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-675805P P 20050427
GI

L5 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB Selected compds. of general formula R-X-W-Y-R1 (wherein R = an aryl or heterocyclic ring or ring system; W = (un)substituted Ph, benzomorpholinyl, C3-7 cycloalkyl, etc.; X = O, S, S(O), SO2, etc.; Y = carboxamido, aminoalkyl, etc.; R1 = a partially unsatd. or saturated ring) are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving cancer and the like. The invention also relates to processes for making such compds. as well as to intermediates useful in such processes. For example, I was prepared by reacting 4-(6,7-dimethoxyquinolin-4-yloxy)-3-fluorobenzenamine and 1-methyl-3-oxo-2-phenyl-5-(pyridin-4-yl)-2,3-dihydro-1H-pyrazole-4-carboxylic acid (preparation given). Biol. testing methods are detailed for measuring the compds. of the invention as antitumor agents, but no specific test results are given.

IT 913378-96-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted cyclic amide derivs. as protein kinase inhibitors for treating hepatocyte growth factor (HGF)-related diseases)

RN 913378-96-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-phenyl-N-[5-[[2-[(1-pyrrolidinylthioxomethyl)amino]-4-pyridinyl]oxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 22 Sep 2006
ACCESSION NUMBER: 2006:982164 HCAPLUS
DOCUMENT NUMBER: 145:356811
TITLE: Preparation of fused heterocyclic kinase inhibitors
INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Huynh, Tram N.; Vaccaro, Wayne; Chen, Xiao-Tao; Kim, Kyoung S.; Cai, Zhen-Wei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 141pp., Cont.-in-part of U.S. Ser. No. 167,043.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006211695	A1	20060921	US 2005-292358	20051201
US 2005288290	A1	20051229	US 2005-167043	20050624
AU 2005259894	A1	20060112	AU 2005-259894	20050628
AU 2005260056	A1	20060112	AU 2005-260056	20050628
CA 2571680	A1	20060112	CA 2005-2571680	20050628
EP 1761268	A2	20070314	EP 2005-791275	20050628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU				

PRIORITY APPLN. INFO.:

US 2004-583459P	P	20040628
US 2004-612563P	P	20040923
US 2005-167043	A2	20050624
WO 2005-US22682	W	20050628
WO 2005-US23099	W	20050628

OTHER SOURCE(S): MARPAT 145:356811
GI



I



II



III

L5 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)nNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100 μM. Pharmaceutical compns. comprising the compound I or II alone or in combination with other antitumor agent are disclosed.

IT 888719-46-8P 888719-48-0P 888719-49-1P
888719-50-4P 888719-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors
for treating cancer)

RN 888719-46-8 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



L5 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 888719-49-1 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-pyrrolidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



L5 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 888719-48-0 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 888719-47-9
CMF C30 H29 F2 N5 O3

PAGE 1-A



L5 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A



RN 888719-50-4 HCAPLUS

CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(4-hydroxy-1-piperidinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 888719-52-6 HCAPLUS

CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L5 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
trifluoromethylphenyl)-2H-isoquinolin-1-one which underwent cyclocondensation with di-Et carbonate in the presence of NaOMe in methanol at 105° for 13 h to give 78% 7-((S)-5-Hydroxymethyl-2-oxooxazolidin-3-yl)-3-(2-trifluoromethylphenyl)-2H-isoquinolin-1-one. The representative compds. I showed IC50 of 0.021-0.96 against the proliferation of human colon cancer HCT116 cells.

IT 908257-27-2P, 2-Oxo-1-[1-oxo-3-(2-trifluoromethylphenyl)-1,2-dihydroisoquinolin-7-yl]pyrrolidine-3-carboxylic acid dimethylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (2H)-isoquinol-1-one derivs. as antitumor agents)

RN 908257-27-2 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-[1,2-dihydro-1-oxo-3-[2-(trifluoromethyl)phenyl]-7-isoquinolinyl]-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 31 Aug 2006
ACCESSION NUMBER: 2006:886855 HCAPLUS
DOCUMENT NUMBER: 145:293033
TITLE: Preparation of 1-(2H)-isoquinolone derivatives as antitumor agents
INVENTOR(S): Hattori, Kazuo; Niizuma, Satoshi; Masubuchi, Miyako; Koyama, Kohei; Kondoh, Osamu; Tsukaguchi, Toshiyuki; Okada, Takehiro
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 366pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090743	A1	20060831	WO 2006-JP303180	20060222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-45926 A 20050222
JP 2005-236919 A 20050817
OTHER SOURCE(S): MARPAT 145:293033
GI



I

AB The title compds. represented by the formula (I), prodrugs thereof, or pharmaceutically acceptable salts of either of them [X = each optionally substituted aryl or heteroaryl; ring Cy = optionally substituted 4-7 membered single heterocyclic ring or 8-10 membered fused heterocyclic ring; Z = O, S, Ra; Ra= H, C1-8 alkyl, aryl-C1-6 alkyl, aryl, heteroaryl]. These compds. are useful for effectively treating and preventing proliferative diseases such as cancers, in particular solid tumors. Thus, ring-opening amination of (R)-glycidol with 7-amino-3-(2-trifluoromethylphenyl)-2H-isoquinolin-1-one in ethanol under refluxing for 3 days gave 63% 7-((R)-2,3-dihydroxypropylamino)-3-(2-

L5 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 08 Jun 2006
ACCESSION NUMBER: 2006:534761 HCAPLUS
DOCUMENT NUMBER: 145:28024
TITLE: Preparation of fused heterocyclic kinase inhibitors
INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Huynh, Tram N.; Vaccaro, Wayne; Chen, Xiao-Tao; Kim, Kyoung S.; Cai, Zhen-Wei
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 141 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288290	A1	20051229	US 2005-167043	20050624
AU 2005259894	A1	20060112	AU 2005-259894	20050628
AU 2005260056	A1	20060112	AU 2005-260056	20050628
CA 2571680	A1	20060112	CA 2005-2571680	20050628
WO 2006004636	A2	20060112	WO 2005-US22682	20050628
WO 2006004636	A3	20060526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

WO 2006004833	A2	20060112	WO 2005-US23099	20050628
WO 2006004833	A3	20060713		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

WO 2006004884	A2	20060112	WO 2005-US23198	20050628
WO 2006004884	A3	20060323		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,

L5 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 1761268 A2 20070314 EP 2005-791275 20050628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU
US 2006211695 A1 20060921 US 2005-292358 20051201
PRIORITY APPLN. INFO.: US 2004-583459P P 20040628
US 2004-612563P P 20040923
US 2005-167043 A2 20050624
WO 2005-US22682 W 20050628
WO 2005-US23099 W 20050628
OTHER SOURCE(S): MARPAT 145:28024
GI


I


II


III

AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100 μM. Pharmaceutical comps. comprising the compound I or II alone or in combination with other antitumor agent are disclosed.

L5 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 888719-47-9
CMF C30 H29 F2 N5 O3

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 888719-49-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-pyrrolidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 888719-46-8P 888719-48-0P 888719-49-1P
888719-50-4P 888719-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors
for treating cancer)
RN 888719-46-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 888719-48-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

L5 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 888719-50-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(4-hydroxy-1-piperidinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 888719-52-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L5 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 08 Jun 2006
ACCESSION NUMBER: 2006:534671 HCAPLUS
DOCUMENT NUMBER: 145:28023
TITLE: Preparation of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer
INVENTOR(S): Borzilleri, Robert M.; Chen, Zhong; Hunt, John T.; Huynh, Tram; Poss, Michael A.; Schroeder, Gretchen M.; Vaccaro, Wayne; Wong, Tai W.; Chen, Xiao-Tao; Kim, Kyoung S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 135 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006004006	A1	20060105	US 2005-167049	20050624
US 7173031	B2	20070206		
AU 2005259894	A1	20060112	AU 2005-259894	20050628
AU 2005260056	A1	20060112	AU 2005-260056	20050628
CA 2571680	A1	20060112	CA 2005-2571680	20050628
WO 2006004636	A2	20060112	WO 2005-US22682	20050628
WO 2006004636	A3	20060526		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004833	A2	20060112	WO 2005-US23099	20050628
WO 2006004833	A3	20060713		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2006004884	A2	20060112	WO 2005-US23198	20050628
WO 2006004884	A3	20060323		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,				

L5 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1761268	A2	20070314	EP 2005-791275	20050628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU				

PRIORITY APPLN. INFO.:

US 2004-583459P	P	20040628
US 2004-612563P	P	20040923
WO 2005-US22682	W	20050628
WO 2005-US23099	W	20050628

OTHER SOURCE(S): MARPAT 145:28023
GI



I II



III

AB The title compds. I and II [R1 = H, alkyl, cycloalkyl, etc.; R2 = H, halo, CN, etc.; B = O, NR8, S, SO, SO2, CR9C10; V = NR11 or (CR47R48)p; W or X = C or N; Y = O, S, NR12; Z = CR13R14, (CR13R14)mNR15; m = 0-2; n = 0-4; p = 0-4, provided that if p = 0, R1 is not Ph; A = substituted pyrrolo[2,1-f][1,2,4]triazin-4-yl, pyrrolo[1,2-b]pyridazin-4-yl, pyrrolo[2,3-b]pyridin-4-yl, etc.; R3, R8, R11, R15 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl, heterocycloalkyl; R9, R10 = H, halo, alkyl, etc.; R12 = H, alkyl, CN, etc.; R13-R15, R47, R48 = H, halo, alkyl, etc.; and their pharmaceutically acceptable salts], useful as protein kinase inhibitors for treating cancer and other protein kinase mediated diseases, were prepared E.g., a multi-step synthesis of III, starting from Et 5-methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, was given. Compds. I and II inhibit the Met kinase with IC50 values between 0.01 to 100 μM. Pharmaceutical compns. comprising the compound I or II alone or in combination with other antitumor agent are disclosed.

IT 888719-46-8P 888719-48-0P 888719-49-1P

L5 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
888719-50-4P 888719-52-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrolopyridines and pyrrolotriazines as kinase inhibitors for treating cancer)

RN 888719-46-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 888719-48-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-piperidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 888719-47-9

L5 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C30 H29 F2 N5 O3

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 888719-49-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-[[3-(1-

L5 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyrrolidinylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 888719-50-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(4-hydroxy-1-piperidinyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 888719-52-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-fluoro-4-[[3-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 205 THERE ARE 205 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 13 Dec 2005
ACCESSION NUMBER: 2005:1299348 HCAPLUS
DOCUMENT NUMBER: 144:192058
TITLE: On the structure of compounds obtained from the reaction of amines with 6,6-dimethyl-5,7-dioxaspiro[2.5]octane-4,8-dione
AUTHOR(S): Rigo, Benoit; Gautret, Philippe
CORPORATE SOURCE: EA 2692, Groupe de Recherche sur l'Inhibition de la Proliferation Cellulaire, Ecole des Hautes Etudes d'Ingenieur, Lille, 59046, Fr.
SOURCE: Tetrahedron Letters (2005), Volume Date 2006, 47(3), 295-298
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:192058
GI



AB Recent literature data on the reaction of aromatic amines with 6,6-dimethyl-5,7-dioxaspiro[2.5]octane-4,8-dione need to be corrected The anal. of NMR data of authentic compds. prepared by standard methods indicated that the structure of the product of reaction of Meldrum's acid derivative I with aniline II, claimed previously to be pyroglutamic acid derivative III (R1 = H; R2 = HO2C), is actually its regioisomer III (R1 = HO2C; R2 = H).

IT 874962-82-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(studies on the reaction of aromatic amines with (dimethyl)dioxaspiro[2.5]octanedione with formation of (oxo)pyrrolidinecarboxylic acids)

RN 874962-82-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N,1-diphenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 02 Dec 2005
ACCESSION NUMBER: 2005:1260610 HCAPLUS
DOCUMENT NUMBER: 144:22946
TITLE: Preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases
INVENTOR(S): Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Chaffee, Stuart C.; Tempest, Paul A.; Olivieri, Philip R.; Johnson, Rebecca E.; Albrecht, Brian K.; Patel, Vinod F.; Cee, Victor J.; Kim, Joseph L.; Bellon, Steven; Zhu, Xiaotian; Cheng, Yuan; Xi, Ning; Romero, Karina; Nguyen, Hanh Nho; Deak, Holly L.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 540 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113494	A2	20051201	WO 2005-US16346	20050509
WO 2005113494	A3	20060316		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005245386	A1	20051201	AU 2005-245386	20050509
CA 2564355	A1	20051201	CA 2005-2564355	20050509
US 2006009453	A1	20060112	US 2005-126000	20050509
EP 1751136	A2	20070214	EP 2005-779977	20050509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				

PRIORITY APPLN. INFO.: US 2004-569193P P 20040507
WO 2005-US16346 W 20050509
OTHER SOURCE(S): MARPAT 144:22946
GI

L5 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The present invention relates to nitrogen-heteroaryl-containing compds. (shown as I; variables defined below; e.g. 4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin-2-yl]amino]-N-[3-[(tetrahydrofuran-2-yl)methoxy]-5-trifluoromethylphenyl]benzamide (shown as II)) and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compds. are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compns., including the compds., and methods of treating disease states related to the activity of protein kinases. For I: A is N or CR10; B is N or CR11; D is N or CR12; E is N or CH; G is NR13, O, S, C(O), S(O), SO2, CR13R13 or CR13R14; H1 is N or CR5; H2 is N or CR6; H3 is N or CR7; H4 is N or CR5; H5 is N or CR9; R1 is H, halo, haloalkyl, NO2, CN, NR13R13, OR13, SR13 (CHR13)nR13, or R15; alternatively R1 taken together with R10 forms a partially or fully unsatd. 5- or 6-membered ring of C atoms optionally including 1-3 heteroatoms = O, N and S, and the ring (un)substituted; R2 is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; each of R3 and R4, independently, is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, prepns. and/or characterization data for >1200 examples of I and intermediates are included. For example, II was prepared in 2 steps starting with condensation of 4-(2-chloropyridin-3-yl)pyrimidine (preparation given) with 3-amino-4-fluorobenzoic acid in Et3N-TFA to give 4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin-2-yl]amino]benzoic acid, which was condensed with [3-[(tetrahydrofuran-2-yl)methoxy]-5-

L5 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

trifluoromethylphenyl]amine using EDC and DMAP in DMF.

IT 870232-86-3P, 1-(4-Methoxyphenyl)-N-[4-[[3-[2-(methylamino)pyrimidin-4-yl]pyridin-2-yl]oxy]phenyl]-2-oxopyrrolidine-3-carboxamide 870232-87-4P, 1-(2-Fluorophenyl)-N-[4-[[3-[2-(methylamino)pyrimidin-4-yl]pyridin-2-yl]oxy]phenyl]-2-oxopyrrolidine-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases)

RN 870232-86-3 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-(4-methoxyphenyl)-N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 870232-87-4 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-(2-fluorophenyl)-N-[4-[[3-[2-(methylamino)-4-

L5 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

pyrimidinyl]-2-pyridinyl]oxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 06 Nov 2005

ACCESSION NUMBER: 2005:1176889 HCAPLUS

DOCUMENT NUMBER: 143:440434

TITLE: Preparation of monocyclic heterocycles as kinase inhibitors, particularly Met kinase, for treating cancer

INVENTOR(S): Borzilleri, Robert M.; Cornelius, Lyndon A. M.; Schmidt, Robert J.; Schroeder, Gretchen M.; Kim, Kyoung S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 128 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005245530	A1	20051103	US 2005-111144	20050421
AU 2005249382	A1	20051215	AU 2005-249382	20050422
CA 2563831	A1	20051215	CA 2005-2563831	20050422
WO 2005117867	A2	20051215	WO 2005-US14120	20050422
WO 2005117867	A3	20060330		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737451	A2	20070103	EP 2005-779444	20050422
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU				
NO 2006005148	A	20061108	NO 2006-5148	20061108
PRIORITY APPLN. INFO.:			US 2004-564842P	P 20040423
			US 2004-639178P	P 20041223
			US 2005-111144	A 20050421
			WO 2005-US14120	W 20050422

OTHER SOURCE(S): MARPAT 143:440434

GI

L5 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II



III

AB The invention is related to compds. of formula I and II [wherein R1 = H, (un)substituted alk(en/yn)yl, hetero/aryl, etc.; each R2 = independently H, halo, CN, NO2, alkyl, etc.; B = O, S, SO, SO2, NH, etc.; V = NH and derivs., (CH2)p and derivs. with proviso; p = 0-4; W, X = independently C, N; Z = CH2 and derivs.; (CH2)q-NH and derivs.; q = 0-2; R3 = H, (un)substituted heterocyclyl, alk(en/yn)yl, cycloalkyl, hetero/aryl, etc.,; R4 = (un)substituted hetero/aryl, heterocycloalkyl with provisos; A = (un)substituted pyridin-4-yl, pyrimidin-4-yl, pyridazin-4-yl, etc.] their enantiomers, diastereomers, hydrates, solvates, and pharmaceutically acceptable salts, as protein kinase, particularly Met kinase, inhibitors and methods for using them for the treatment of cancer. E.g., a 4 step synthesis of pyrimidine II, starting from 2,4-dichloropyrimidine and N-(3-fluoro-4-hydroxyphenyl)acetamide, was given. Preferred compds. I inhibited Met kinase with IC50 values between 0.01 and 100 μM.

IT 868736-32-7P, N-[4-(2-Aminopyridin-4-yloxy)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxopyrrolidine-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of monocyclic heterocycles as kinase inhibitors
for treating cancer)

RN 868736-32-7 HCAPLUS

CN 3-Pyrrolidinecarboxamide, N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L5 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 28 Jun 2005

ACCESSION NUMBER: 2005:556318 HCAPLUS

DOCUMENT NUMBER: 144:31943

TITLE: 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. [Erratum to document cited in CA142:475248]

AUTHOR(S): Pevarello, Paolo; Brasca, Maria Gabriella; Orsini, Paolo; Traquandi, Gabriella; Longo, Antonio; Nesi, Marcella; Orzi, Fabrizio; Piutti, Claudia; Sansonna, Pietro; Varasi, Mario; Cameron, Alexander; Vulpetti, Anna; Roletto, Fulvia; Alzani, Rachele; Ciomei, Marina; Albanese, Clara; Pastori, Wilma; Marsiglio, Aurelio; Pesenti, Enrico; Fiorentini, Francesco; Bischoff, Jim R.; Mercurio, Ciro

CORPORATE SOURCE: Departments Chemistry and Biology, BU-Oncology and BU-Preclinical Science, Nerviano Medical Sciences, Nerviano, 20014, Italy

SOURCE: Journal of Medicinal Chemistry (2005), 48(15), 5058
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB On page 2945, compds. 43, 44, and 15a in Scheme 4 were drawn incorrectly. The corrected structures of the regioisomers are given in accordance with the final derivative 15 on page 2947. On page 2952, the names of compds. 43 and 15a in the Exptl. Section are incorrect. The correct name for compound 43 is 1-[4-(1-methoxycarbonylethyl)phenyl]-2-oxopyrrolidine-3-carboxylic acid; the correct name for compound 15a is 2-[4-(3-carbamoyl-2-oxopyrrolidin-1-yl)phenyl]propionic acid.

IT 437983-18-1P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and lead optimization of 3-aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents (Erratum))

RN 437983-18-1 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-[4-[2-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-methyl-2-oxoethyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



IT 852068-61-2P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and lead optimization of 3-aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents (Erratum))

RN 852068-61-2 HCAPLUS

CN Benzeneacetic acid, 4-[3-(aminocarbonyl)-2-oxo-1-pyrrolidinyl]-α-methyl- (9CI) (CA INDEX NAME)

L5 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 852068-60-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and lead optimization of 3-aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents (Erratum))

RN 852068-60-1 HCAPLUS

CN Benzeneacetic acid, 4-[3-(aminocarbonyl)-2-oxo-1-pyrrolidinyl]-α-methyl-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 29 Mar 2005
ACCESSION NUMBER: 2005:267083 HCAPLUS
DOCUMENT NUMBER: 142:475248
TITLE: 3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization
AUTHOR(S): Pevarello, Paolo; Brasca, Maria Gabriella; Orsini, Paolo; Traquandi, Gabriella; Longo, Antonio; Nesi, Marcella; Orzi, Fabrizio; Piutti, Claudia; Sansonna, Pietro; Varasi, Mario; Cameron, Alexander; Vulpetti, Anna; Roletto, Fulvia; Alzani, Rachele; Ciomei, Marina; Albanese, Clara; Pastori, Wilma; Marsiglio, Aurelio; Pesenti, Enrico; Fiorentini, Francesco; Bischoff, Jim R.; Mercurio, Ciro
CORPORATE SOURCE: Departments Chemistry and Biology, BU-Oncology and BU-Preclinical Science, Nerviano Medical Sciences, Nerviano, 20014, Italy
SOURCE: Journal of Medicinal Chemistry (2005), 48(8), 2944-2956
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:475248

AB Inhibitors of cyclin-dependent kinases (CDK) such as CDK2/cyclin A-E are currently undergoing clin. trials to verify their potential as new anticancer agents. In a previous article we described the lead discovery process of a 3-aminopyrazole class of CDK2/cyclin A-E inhibitors. The endpoint of this process was PNU-292137, a compound endowed with in vivo antitumor activity in a mouse tumor xenograft model. We optimized this lead compound to improve some physicochem. properties, notably solubility and plasma protein binding. This lead optimization process brought us to the discovery of (2S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]propanamide (PHA-533533, 13), a compound with a balanced activity vs druglike profile. Compound 13 inhibited CDK2/cyclin A with a Ki of 31 nM, counteracting tumor cell proliferation of different cell lines with an IC50 in the submicromolar range. Solubility was improved more than 10 times over the starting lead, while plasma protein binding was decreased from 99% to 74%. With exploitation of this globally enhanced in vitro profile, 13 was more active than PNU-292137 in vivo in the A2780 xenograft model showing a tumor growth inhibition of 70%. Proof of mechanism of action was obtained in vivo by immunohistochem. anal. of tumor slices of 13-treated vs untreated animals.

IT 852068-60-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and lead optimization of 3-aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents)

RN 852068-60-1 HCAPLUS
CN Benzeneacetic acid, 4-[3-(aminocarbonyl)-2-oxo-1-pyrrolidinyl]-α-methyl-, methyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 07 May 2004
ACCESSION NUMBER: 2004:370902 HCAPLUS
DOCUMENT NUMBER: 140:375065
TITLE: Preparation of 2-oxo-1-phenylpyrrolidine-3-carboxamides as herbicides.
INVENTOR(S): Reinhard, Robert; Hamprecht, Gerhard; Puhl, Michael; Seitz, Werner; Parra Rapado, Liliana; Scannell-Lansky, Annegret; Grossmann, Klaus; Schiffer, Helmut; Witschel, Matthias; Zagar, Cyrill; Landes, Andreas; Rack, Michael
PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037787	A1	20040506	WO 2003-EP11557	20031017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502478	A1	20040506	CA 2003-2502478	20031017
AU 2003274037	A1	20040513	AU 2003-274037	20031017
EP 1556346	A1	20050727	EP 2003-758015	20031017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006513995	T	20060427	JP 2004-545882	20031017
US 2006019831	A1	20060126	US 2005-531573	20050418
PRIORITY APPLN. INFO.:			DE 2002-10248700 A	20021018
			WO 2003-EP11557 W	20031017

OTHER SOURCE(S): MARPAT 140:375065
GI



I

AB Title compds. [I; R1 = H, OH, Cl, Br, alkyl, cycloalkyl, alkenyl, alkynyl, COR4, CO2R4; R2, R3 = H, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, Ph, heterocyclyl, etc.; R3NAnR2 = atoms to form a (substituted) 3-7 membered heterocyclyl; R20-R24 = H, OH, cyano, NO2, halo, alkyl, cycloalkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, alkoxy, haloalkoxy, alkylthio, COR4, alkoxyalkyl, etc.; X, Y = O, S; n = 0, 1; A = O, S, SO, SO2, NR12; R4 = H, alkyl; R12 = H, alkyl, alkenyl, alkynyl], were prepd. Thus, 3-trifluoromethylaniline, butyrolactone, and conc. HCl were refluxed 13 h to give 85% 1-(3-trifluoromethyl)phenyl-2-pyrrolidinone. The latter in THF at 0° was treated with LDA and 45 min. later with di-Me carbonate in THF followed by warming to 20° and stirring for 72 h to give 34% 2-oxo-1-(3-trifluoromethyl)phenyl-3-pyrrolidinecarboxylic acid. This was stirred with carbonyldiimidazole and aq. MeNH2 in CH2Cl2 to give 32% 1-(3-trifluoromethyl)phenyl-3-(N-methyl)carboxamido-2-pyrrolidinone. I at 3 kg/ha postemergent gave very good herbicidal activity against e.g. velvetleaf.

IT 685531-31-1P 685531-32-2P 685531-33-3P
685531-34-4P 685531-35-5P 685531-36-6P
685531-37-7P 685531-38-8P 685531-39-9P
685531-40-2P 685531-41-3P 685531-42-4P
685531-43-5P 685531-44-6P 685531-45-7P
685531-46-8P 685531-47-9P 685531-48-0P
685531-49-1P 685531-50-4P 685531-51-5P
685531-52-6P 685531-53-7P 685531-54-8P
685531-55-9P 685531-56-0P 685531-57-1P
685531-58-2P 685531-59-3P 685531-60-6P
685531-61-7P 685531-62-8P 685531-63-9P
685531-64-0P 685531-65-1P 685531-66-2P
685531-67-3P 685531-68-4P 685531-69-5P
685531-70-8P 685531-71-9P 685531-72-0P
685531-73-1P 685531-74-2P 685531-75-3P
685531-76-4P 685531-77-5P 685531-78-6P
685531-79-7P 685531-80-0P 685531-81-1P
685531-82-2P 685531-83-3P 685531-84-4P
685531-85-5P 685531-86-6P 685531-87-7P
685531-88-8P 685531-89-9P 685531-90-2P
685531-91-3P 685531-92-4P 685531-93-5P
685531-94-6P 685531-95-7P 685531-96-8P
685531-97-9P 685531-98-0P 685531-99-1P
685532-00-7P 685532-01-8P 685532-02-9P
685532-03-0P 685532-04-1P 685532-05-2P
685532-06-3P 685532-07-4P 685532-08-5P
685532-09-6P 685532-10-9P 685532-11-0P
685532-12-1P 685532-13-2P 685532-14-3P
685532-15-4P 685532-16-5P 685532-17-6P
685532-18-7P 685532-19-8P 685532-20-1P
685532-21-2P 685532-22-3P 685532-23-4P
685532-25-6P 685532-26-7P 685532-27-8P
685532-28-9P 685532-29-0P 685532-30-3P
685532-31-4P 685532-32-5P 685532-33-6P
685532-34-7P 685532-35-8P 685532-36-9P
685532-37-0P 685532-38-1P 685532-39-2P
685532-40-5P 685532-41-6P 685532-42-7P
685532-43-8P 685532-44-9P 685532-45-0P
685532-46-1P 685532-47-2P 685532-48-3P
685532-49-4P 685532-50-7P 685532-51-8P
685532-52-9P 685532-53-0P 685532-54-1P
685532-55-2P 685532-56-3P 685532-57-4P
685532-58-5P 685532-59-6P 685532-60-9P
685532-61-0P 685532-62-1P 685532-63-2P
685532-64-3P 685532-65-4P 685532-66-5P
685532-67-6P 685532-68-7P 685532-69-8P
685532-70-1P 685532-71-2P 685532-72-3P
685532-73-4P 685532-74-5P 685532-75-6P

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
685532-76-7P 685532-77-8P 685532-78-9P
685532-79-0P 685532-80-3P 685532-81-4P
685532-82-5P 685532-83-6P 685532-84-7P
685532-85-8P 685532-86-9P 685532-87-0P
685532-88-1P 685532-89-2P 685532-90-5P
685532-91-6P 685532-92-7P 685532-93-8P
685532-94-9P 685532-95-0P 685532-96-1P
685532-97-2P 685532-98-3P 685532-99-4P
685533-00-0P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxophenylpyrrolidinecarboxamides as herbicides)

RN 685531-31-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-32-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 3-(acetyloxy)-2-oxo-N-phenyl-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-33-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-37-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-cyclohexyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-38-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(cyclopropylmethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-34-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-propyl-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-35-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-butyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-36-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-methylethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 685531-39-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethoxy)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-40-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-methyl-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-41-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-ethyl-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-42-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-propyl-1-[3-(trifluoromethoxy)phenyl]-

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 685531-43-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-44-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-cyclopentyl-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-45-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-phenyl-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-49-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-50-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-methoxy-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-51-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-3-methyl-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-46-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-methylethyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-47-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-cyclopropyl-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-48-0 HCAPLUS

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-52-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-(phenylmethoxy)-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-53-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-methylethoxy)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-54-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-(2-propenyloxy)-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-55-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[(2-chloro-2-propenyl)oxy]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-56-0 HCAPLUS
CN Isoxazolidine, 2-[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)



388/240

RN 685531-57-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-butenyloxy)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-61-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(cyclohexyloxy)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-62-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(cyclohexylmethoxy)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-58-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[(3-chloro-2-propenyl)oxy]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-59-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-ethoxy-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-60-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-methoxyethoxy)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-63-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[3-(1-methylethyl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-64-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-3-methyl-1-[3-(1-methylethyl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 685531-65-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethoxy)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-66-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(2-chlorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-67-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-chlorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 685531-68-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3,5-dichlorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-69-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(2,4-dichlorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-70-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(2-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-71-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-72-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-73-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(2-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-74-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-75-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(4-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-76-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[2-(1-methylethyl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-77-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-78-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(4-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-79-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-chlorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 3-Pyrrolidinecarboxamide, N-(1-ethylcyclohexyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-83-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1,1-dimethyl-2-(methylthio)ethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-84-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(6-methylbicyclo[3.2.0]hept-6-yl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-80-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethyl-2-propynyl)-1-(3-methoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685531-81-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-(ethylthio)-1,1-dimethylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-82-2 HCAPLUS

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-85-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-(2-chlorophenyl)-1,1-dimethylpropyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-86-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-(3-chlorophenyl)-1,1-dimethylpropyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 685531-87-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-methyl-1-(4-methylphenyl)ethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-88-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-methyl-1-(3-methylphenyl)ethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-89-9 HCAPLUS
CN Tyrosine, 3-methoxy-O,α-dimethyl-N-[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-90-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-(3-methoxyphenyl)-1,1-dimethylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-91-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-(3,4-dimethoxyphenyl)-1,1-dimethylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-92-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-ethyl-1-methylpropyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-93-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-(3,4-dichlorophenyl)-1,1-dimethylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-94-6 HCAPLUS
CN Cyclohexanecarboxylic acid, 1-[[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 685531-95-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylbutyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 685531-98-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethyl-2-propynyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-99-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-cyano-1-methylethyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-00-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-(1,1,3,3-tetramethylbutyl)-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-01-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-(1-phenylcyclopropyl)-1-[3-

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685531-96-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-(tetrahydro-4-methyl-2H-pyran-4-yl)-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685531-97-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-methyl-1-phenylethyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-02-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-(4-methoxyphenyl)cyclopropyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-03-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-(4-methoxyphenyl)-1,1-dimethylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-04-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-(4-chlorophenyl)cyclopentyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-05-2 HCAPLUS
CN Butanoic acid, 3-methyl-3-[[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-08-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1,2-dimethyl-1-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]propyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-06-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-07-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-methyl-1-[3-(trifluoromethyl)phenyl]ethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A

RN 685532-09-6 HCAPLUS
CN Cyclopropanecarboxylic acid, 1-[[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 685532-10-9 HCAPLUS
CN Tyrosine, α-methyl-N-[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-11-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-ethynyl-1-methylbutyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-12-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-ethyl-1-methylpentyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-15-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-[tetrahydro-4-methyl-2-(1-methylethyl)-2H-pyran-4-yl]-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-16-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-(tetrahydro-4-methyl-2-propyl-2H-pyran-4-yl)-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-13-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1,1-dimethyl-2-(1-methylethyl)-3-butynyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-14-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-ethyltetrahydro-4-methyl-2H-pyran-4-yl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-17-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethyl-2-phenylpropyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-18-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[2-(4-fluorophenyl)-1,1-dimethylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-19-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-diethyl-2-propynyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-20-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-(tetrahydro-3-methyl-1,1-dioxido-3-thienyl)-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-26-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-N-(1-ethynylcyclohexyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-27-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-N-(1-ethylcyclohexyl)-2-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 685532-21-2 HCAPLUS
CN Tryptophan, α-methyl-N-[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 685532-22-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-2-oxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 685532-23-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-N-(1,1-dimethyl-2-propynyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-25-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 685532-28-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-2-oxo-N-(tetrahydro-4-methyl-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 685532-29-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-30-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-N-ethyl-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-31-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(difluoromethoxy)phenyl]-N-(1-methylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-32-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-cyclopropyl-1-[3-(difluoromethoxy)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-33-6 HCAPLUS

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-36-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[4-(1-methylethyl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-37-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-(difluoromethoxy)phenyl]-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-38-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-(3,4,5-trichlorophenyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 3-Pyrrolidinecarboxamide, 1-[4-(2,2-dichloroethenyl)phenyl]-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-34-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3,5-bis(trifluoromethyl)phenyl]-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-35-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[4-(methylthio)phenyl]-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-39-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3,5-dibromophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-40-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-chloro-4-nitrophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-41-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-[4-(pentafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-42-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethyl-2-propenyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-43-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylpropyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-44-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-hydroxy-1,1-dimethylethyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-45-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1-cyano-1-methylpropyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-46-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2-cyano-1,1-dimethylethyl)-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-47-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-chloro-3-(trifluoromethyl)phenyl]-N-(1,1-

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-48-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3,5-dimethoxyphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-49-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[3-(methylthio)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-50-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[3-(1,1-dimethylethyl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-51-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[3-(1-methylethoxy)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-52-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3,4-difluorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-53-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-54-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-(4-propylphenyl)-(9CI) (CA INDEX NAME)



RN 685532-55-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-(1,1-dimethylethoxy)phenyl]-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-59-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[4-(ethylthio)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-60-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-bromo-5-chloro-4-methoxyphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-61-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-chloro-4-propoxyphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 685532-56-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-chloro-4-fluorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-57-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-2-oxo-1-(4-propoxyphenyl)-(9CI) (CA INDEX NAME)



RN 685532-58-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-bromophenyl)-N-(1,1-dimethylethyl)-2-oxo-(9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-62-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-fluoro-4-nitrophenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-63-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3,5-dibromo-4-chlorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-64-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-ethyl-5-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-65-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3,5-dimethylphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-66-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-bromophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-67-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-ethylphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-68-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[4-methoxy-3-(1-methylethyl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-69-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-70-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-cyanophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-71-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-cyano-4-methoxyphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-72-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-cyano-4-fluorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-73-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-fluoro-4-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-74-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-chloro-3-cyanophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-75-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3,4-dichlorophenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-76-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(4-fluoro-3-methylphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-77-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-chloro-4-methoxyphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-78-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(4-heptylphenyl)-2-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-82-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-chloro-4-methylphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-83-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-84-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-methyl-5-propylphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 685532-79-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-[4-(1,1-dimethylethyl)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-80-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(4-ethylphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-81-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-chloro-4-(1-methylethyl)phenyl]-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-85-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3,5-diethylphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-86-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(3-ethoxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-87-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-bromo-3-methoxyphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-88-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(4-chloro-3-methoxyphenyl)-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-89-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-chloro-4-[(trifluoromethyl)thio]phenyl]-N-(1,1-dimethylethyl)-2-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 685532-93-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-methyl-1-(2-methylphenyl)ethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 685532-90-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(1,1-dimethylethyl)-1-(4-fluorophenyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 685532-91-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-92-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[3-(4-chlorophenyl)-1,1-dimethylpropyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-94-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 685532-95-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-(aminocarbonyl)-1,2-dimethylpropyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-96-1 HCAPLUS
CN Alanine, 2-methyl-N-[[2-oxo-1-[3-(trifluoromethoxy)phenyl]-3-pyrrolidinyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 685532-97-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-(3-chlorophenyl)-1-methylethyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685532-98-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[3-(trifluoromethoxy)phenyl]-N-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 685532-99-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[3-(trifluoromethoxy)phenyl]-N-(1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 685533-00-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1,3-bis(2-ethylhexyl)hexahydro-5-pyrimidinyl]-2-oxo-1-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 01 Apr 2004
ACCESSION NUMBER: 2004:267295 HCAPLUS
DOCUMENT NUMBER: 140:287260
TITLE: Preparation of 4-pyrrolidinophenyl benzyl ether derivatives as monoamine oxidase B inhibitors
INVENTOR(S): Jolidon, Synese; Rodriguez-Sarmiento, Rosa Maria; Thomas, Andrew William; Wostl, Wolfgang; Wyler, Rene
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026826	A1	20040401	WO 2003-EP10383	20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498335	A1	20040401	CA 2003-2498335	20030918
AU 2003273901	A1	20040408	AU 2003-273901	20030918
US 2004097578	A1	20040520	US 2003-666594	20030918
US 2004106650	A1	20040603	US 2003-667088	20030918
US 7037935	B2	20060502		
US 2004116707	A1	20040617	US 2003-667087	20030918
US 7151111	B2	20061219		
EP 1542971	A1	20050622	EP 2003-757866	20030918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014314	A	20050726	BR 2003-14314	20030918
CN 1681777	A	20051012	CN 2003-821256	20030918
CN 1681778	A	20051012	CN 2003-821767	20030918
CN 1681779	A	20051012	CN 2003-821952	20030918
JP 2006503834	T	20060202	JP 2004-537120	20030918
NO 2005000701	A	20050302	NO 2005-701	20050209
ZA 2005001557	A	20050908	ZA 2005-1557	20050222
US 2006122235	A1	20060608	US 2006-325747	20060105
US 7122562	B2	20061017		

PRIORITY APPLN. INFO.:	EP 2002-21319	A	20020920
	US 2003-667088	A3	20030918
	WO 2003-EP10383	W	20030918

OTHER SOURCE(S): MARPAT 140:287260
GI

L5 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB Title compds. I [R = (un)substituted Ph; X-Y = CH2CH2, CH:CH, CH2O; R1-R3 = H, halogen; R4 = H, halogen, Me; R5 = (un)substituted CONH2, NH2] were prepared for use in the prevention and treatment of illness mediated by monoamine oxidase B, in particular Alzheimer's disease or senile dementia (no data). Thus, 4-PhCH2OC6H4NH2 was treated with BrCH2CH2CHBrCOCl and the resulting amide cyclized with Dowex 2X10 to give 1-(4-benzyloxyphenyl)-3-bromo-2-pyrrolidinone which was treated with NaCN to give the 3-cyano analog.

IT 676232-63-6P 676232-64-7P 676232-65-8P
676232-66-9P 676232-67-0P 676232-68-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-pyrrolidinophenyl benzyl ether derivs. as monoamine oxidase B inhibitors)

RN 676232-63-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(3-fluorophenyl)methoxy]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 676232-64-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676232-65-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(4-fluorophenyl)methoxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 676232-66-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[4-[(4-fluorophenyl)methoxy]phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 676232-67-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 2-oxo-1-[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 676232-68-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-methyl-2-oxo-1-[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 23 May 2003
ACCESSION NUMBER: 2003:396877 HCAPLUS
DOCUMENT NUMBER: 138:401769
TITLE: Preparation of [1-[3-(indol-3-yl)propanoyl]-1,2,3,4-tetrahydroquinolin-3-ylmethyl]amine derivatives as somatostatin receptor binding inhibitors
INVENTOR(S): Abe, Hidenori; Kasai, Shizuo; Takekawa, Shiro; Watanabe, Masanori
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042204	A1	20030522	WO 2002-JP10800	20021017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003192682	A	20030709	JP 2002-303222	20021017
EP 1437351	A1	20040714	EP 2002-775363	20021017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005245571	A1	20051103	US 2004-492420	20040412
PRIORITY APPLN. INFO.:			JP 2001-322897 A	20011019
			WO 2002-JP10800 W	20021017

OTHER SOURCE(S): MARPAT 138:401769
GI



I

AB The title compds. represented by the formula (I) (wherein X and X1 are the

L5 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
same or different and each represents H, halo, or (un)substituted NH2; R1 and R2 are the same or different and each represents H or (un)substituted C1-6 alkyl; or NR1R2 forms (un)substituted N-contg. heterocyclic ring; R3 represents an each optionally substituted hydrocarbon group or heterocyclyl; R4 represents H or an each optionally substituted hydrocarbon group or heterocyclyl; Y and Ya are the same or different and each represents a bond or a spacer having a C1-8 main chain; and Z and Za are the same or different and each represents H, halo, or (un)substituted cyclic group), salts of the compds., or prodrugs of either are prepd. They have inhibitory activity against somatostatin receptor, in particular somatostatin receptor subtype 2 binding and are agonists of somatostatin receptor and effective in the prevention of and treatment for diseases in which somatostatin participates, in particular diabetes or diabetes complications. Thus, a soln. of 2.6 g (2RS,3SR)-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-(1H-indol-3-yl)butanoic acid and 0.06 mL DMF in 60 mL THF was treated dropwise with a soln. of 0.63 mL oxalyl chloride in 5 mL THF at 0°, stirred at 0° for 30 min, concd., treated with 30 mL THF, and reconcd., dissolved in 30 mL THF, added dropwise at 0° to a soln. of 1-[(3S)-6-chloro-1,2,3,4-tetrahydroquinolin-3-yl]-N,N-dimethylmethaneamine 0.90 g, tetrabutylammonium hydrogen sulfate 0.04 g, and NaOH powder 0.34 g, stirred at 0° for 30 min to give, after workup and silica gel chromatog., a yellow amorphous solid which was stirred with 0.2 mL piperidine in 20 mL methanol at room temp. for 16 h to give, after alumina chromatog., 49% (2RS,3SR)-1-[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]-3-(1H-indol-3-yl)-1-oxo-2-butanamine (II; R = H). WSC (0.10 g) was added to a soln. of II 0.20, 1-[(1-methyl-1H-indol-2-yl)carbonyl]-4-piperidinecarboxylic acid 0.15 g, and HOBt 0.08 g in 10 mL MeCN, stirred at room temp. for 16 h to give, after workup and silica gel chromatog., 64% II (R = Q). II (R = Q1) in vitro inhibited the binding of 125I-somatostatin-14 to human somatostatin receptor protein subtype 2, 3, and 5 with showed IC50 of 0.05, 3, and 10, resp. A tablet formulation contg. II (R = H) was described.
IT 528893-07-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of [[(indolylpropanoyl)tetrahydroquinolinyl]methyl]amine derivs. as somatostatin receptor binding inhibitors (agonists) for prevention or treatment of diabetes or diabetes complications)
RN 528893-07-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[1-[[(3R)-6-chloro-3-[(dimethylamino)methyl]-3,4-dihydro-1(2H)-quinolinyl]carbonyl]-2-(1H-indol-3-yl)propyl]-2-oxo-1-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 528893-06-3
CMF C35 H38 Cl N5 O3

Absolute stereochemistry.

L5 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 21 Jun 2002
ACCESSION NUMBER: 2002:465980 HCAPLUS
DOCUMENT NUMBER: 137:47193
TITLE: Preparation of 5-cycloalkyl-3-(phenylacetamido)-1H-pyrazole cdk inhibitors as antitumor agents
INVENTOR(S): Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella; Brasca, Maria Gabriella; Amici, Raffaella; Villa, Manuela; Piutti, Claudia; Varasi, Mario; Longo, Antonio
PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048114	A1	20020620	WO 2001-EP13617	20011122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6455559	B1	20020924	US 2001-907943	20010719
CA 2430151	A1	20020620	CA 2001-2430151	20011122
AU 2002015053	A5	20020624	AU 2002-15053	20011122
EP 1345909	A1	20030924	EP 2001-983600	20011122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517840	T	20040617	JP 2002-549645	20011122
NZ 525892	A	20041126	NZ 2001-525892	20011122
US 2004019046	A1	20040129	US 2003-432119	20030519
PRIORITY APPLN. INFO.:			US 2000-252911P P	20001127
			US 2001-907943 A	20010719
			WO 2001-EP13617 W	20011122

OTHER SOURCE(S): MARPAT 137:47193
GI

L5 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Title compds. I [wherein R = (un)substituted cycloalkyl; R1 and R2 = independently H, halo, NH2, OH, perfluoroalkyl, alkoxy, (amino)alkyl, or hydroxyalkyl; or R1R2 = :CH2, or cycloalkyl; R3 = (un)substituted 5-6 membered N-containing heterocycle optionally condensed with a carbocyclic or heterocyclic ring on the 3 or 4 position of the Ph; R4 = independently H, OH, alkyl, perfluoroalkyl, or alkoxy; m = 0-4; with provisos; or pharmaceutically acceptable salts thereof] were prepared as cyclin dependent kinase (cdk) inhibitors. For example, amidation of 2-[4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]propanoic acid with tert-Bu 5-amino-3-cyclopropyl-1H-pyrazole-1-carboxylate (preparation of starting materials given) afforded II (41%). (2S)-II exhibited remarkable cdk inhibitory activity with IC50 of 8 nM against cdk2/A. Thus, I are useful in the treatment of cell proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity (no data).

IT 437983-17-0P, 1-[4-[2-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]phenyl]-2-oxo-3-pyrrolidinecarboxamide 437983-18-1P, 1-[4-[2-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-1-methyl-2-oxoethyl]phenyl]-2-oxo-3-pyrrolidinecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(cdk inhibitor; preparation of (cycloalkyl)(phenylacetamido)pyrazole cdk inhibitors as antitumor agents)

RN 437983-17-0 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-[4-[2-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 437983-18-1 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 1-[4-[2-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-1-methyl-2-oxoethyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 17 Feb 2002

ACCESSION NUMBER: 2002:123660 HCAPLUS

DOCUMENT NUMBER: 136:325467

TITLE: Iodine(V) Reagents in Organic Synthesis. Part 3. New Routes to Heterocyclic Compounds via o-Iodoxybenzoic Acid-Mediated Cyclizations: Generality, Scope, and Mechanism

AUTHOR(S): Nicolaou, K. C.; Baran, P. S.; Zhong, Y.-L.; Barluenga, S.; Hunt, K. W.; Kranich, R.; Vega, J. A.

CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA

SOURCE: Journal of the American Chemical Society (2002), 124(10), 2233-2244
CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:325467

AB N-aryl amides (anilides), carbamates, and ureas with pendant alkenes undergo o-iodoxybenzoic acid (IBX)-mediated radical cyclization reactions to give N-aryl δ-lactams, five-membered cyclic carbamates, and five-membered cyclic ureas in good yields. Amino alcs. are prepared by the cyclization of N-aryl carbamates followed by hydrolysis of the N-aryl cyclic carbamates with sodium hydroxide in ethanol. 1-Deoxy amino sugars, amino sugars, and amino sugar lactones can be prepared chemo- and stereoselectively from glycals by IBX-mediated cyclization of N-(4-methoxyphenyl) carbamates prepared from the hydroxy glycals followed by oxidative cleavage of the p-methoxyphenyl moieties and hydrolysis of the carbamates. The use of anhydrous IBX in THF leads to 1-deoxy amino sugar N-aryl carbamates as the sole products. The use of IBX in a THF:DMSO:H2O mixture leads to the N-aryl amino sugar carbamates, while the use of 4-6 equivalent of IBX in THF:H2O gives mixts. of the N-aryl amino sugar carbamates and the N-aryl amino sugar lactone carbamates. These procedures were used in a short synthesis of the amino sugar L-vancosamine. Hammett correlations of 4-substituted anilides, the rearrangement of an N-aryl diphenylcyclopropylpentenoyl amide during IBX-mediated cyclization, and studies of the oxidation potentials and cyclization rates of a set of N-aryl-N-(phenylthio) amides support a mechanism invoking single electron transfer from an anilide mol. to a solvent-activated mol. of IBX, followed by loss of a proton, radical 5-exo-trig cyclization, and loss of a hydrogen atom to produce the observed products. The cyclization of anilides to δ-lactams mediated by IBX can also be performed on solid phase.

IT 413188-21-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-aryl-δ-lactams by regioselective IBX-mediated radical cyclizations of N-aryl amides)

RN 413188-21-3 HCAPLUS

CN 7-Azabicyclo[4.2.1]nonane-1-carboxamide, N,7-bis(4-methoxyphenyl)-8-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 07 Aug 1993
ACCESSION NUMBER: 1993:443346 HCAPLUS
DOCUMENT NUMBER: 119:43346
TITLE: Preparation of 4-ethyl-1-phenyl-3-pyrrolidinecarboxamides ad herbicides.
INVENTOR(S): Moryasu, Koichi; Tomitani, Kanji; Miura, Tooru; Nishida, Makoto; Hibi, Sachiko; Kishi, Daisuke; Oda, Kengo
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05043543	A	19930223	JP 1991-201649	19910812
PRIORITY APPLN. INFO.:			JP 1991-201649	19910812

OTHER SOURCE(S): MARPAT 119:43346
GI



I

AB Herbicides contain 4-ethyl-1-phenyl-3-pyrrolidinecarboxamides I (X = H, halo, CF3, lower alkyl, lower alkoxy, CN, lower alkylthio; n = 1, 2). 3-Phenoxyaniline 10, K2CO3 8.7, and 1-chloro-2-butene 9 g were stirred with DMF at 60-80° for 1 h to give 3.9 g N-(2-butenyl)-3-phenoxyaniline (II). II (3.7 g) was stirred with 3.2 g CCl3COCl in CH2Cl2 and pyridine for 1 h to give 5.2 g N-(2-butenyl)-N-(3-phenoxyphenyl)-2,2,2-trichloroacetamide, which (5.8 g) was refluxed with Bt3SnH and AIBN for 10 min to give 3.1 g 4-ethyl-1-(3-phenoxyphenyl)-2-pyrrolidinone (III). A hexane solution containing diisopropylamine and BuLi was added dropwise to anhydrous THF at -78°, followed by the addition of a THF solution containing 5.6 g III. The mixture was stirred for 30 min and ClCO2Et was added dropwise, to give 6.2 g 4-ethyl-3-ethoxycarbonyl-1-(3-phenoxyphenyl)-2-pyrrolidinone (IV). IV (1.0 g) was added to a MeOH solution containing MeNH2 and the mixture was stirred at room temperature for 8 h to give 0.7 g 4-ethyl-3-(N-methyl)carboxamido-1-(3-phenoxyphenyl)-2-pyrrolidinone (V). V (at 0.4 kg/ha) showed total pre-emergence control of Echinochloa oryzicola, Monochoria vaginalis, Scirpus juncoides, and Lindernia procumbens , with little damage to rice, vs. less herbicidal effect, for 1-(3-trifluoromethylphenyl)-3-chloro-4-chloromethyl-2-pyrrolidinone. Formulation examples are also given.

IT 148260-06-4P 148260-07-5P 148260-08-6P

L5 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 148260-09-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-1-[3-(2-methoxyphenoxy)phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 148260-10-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-methyl-1-[3-[4-(methylthio)phenoxy]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 148260-11-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-methyl-2-oxo-1-[3-[4-(trifluoromethyl)phenoxy]phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
148260-09-7P 148260-10-0P 148260-11-1P
148260-12-2P 148260-13-3P 148260-14-4P
148260-15-5P 148260-16-6P 148260-17-7P
148260-18-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and herbicidal activity of)

RN 148260-06-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-methyl-2-oxo-1-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 148260-07-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-methyl-1-[3-(4-methylphenoxy)phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 148260-08-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-1-[3-(4-methoxyphenoxy)phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 148260-12-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(4-chlorophenoxy)phenyl]-4-ethyl-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 148260-13-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(2,6-difluorophenoxy)phenyl]-4-ethyl-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 148260-14-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-1-[3-(2-fluorophenoxy)phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 148260-15-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(2-chlorophenoxy)phenyl]-4-ethyl-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 148260-16-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(2,4-difluorophenoxy)phenyl]-4-ethyl-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 148260-17-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-1-[3-(4-fluorophenoxy)phenyl]-N-methyl-2-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 148260-18-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-[3-(4-cyanophenoxy)phenyl]-4-ethyl-N-methyl-2-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 09 Jun 1990
ACCESSION NUMBER: 1990:212480 HCAPLUS
DOCUMENT NUMBER: 112:212480
TITLE: Preparation of 1-phenyl-3-carboxyamidopyrrolidones as herbicides
INVENTOR(S): Woolard, Frank X.
PATENT ASSIGNEE(S): ICI Americas, Inc., USA
SOURCE: U.S., 12 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4874422	A	19891017	US 1988-290139	19881227
WO 9007500	A1	19900712	WO 1989-US5402	19891129
W: AU, BR, HU, JP				
RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE				
AU 9047505	A	19900801	AU 1990-47505	19891129
EP 451168	A1	19911016	EP 1990-900526	19891129
EP 451168	B1	19940615		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04503947	T	19920716	JP 1990-500778	19891129
JP 2812553	B2	19981022		
CA 2006543	A1	19900627	CA 1989-2006543	19891222
CA 2006543	C	19970520		

PRIORITY APPLN. INFO.: US 1988-290139 A 19881227
WO 1989-US5402 A 19891129
OTHER SOURCE(S): CASREACT 112:212480; MARPAT 112:212480
GI



I

AB The title compds. I (R1 = H, alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl; R2R2 = alkylene, alkyleneoxyalkylene; R3 = alkyl, alkenyl; R4 = H, halo, Me, CF3, CF2CHF2, etc.; X = H, halo; Y, Z = O, S; n = 0, 1) are prepared as herbicides. 1-(3-Trifluoromethyl)phenyl-3-chlorocarbonyl-4-ethyl-2-pyrrolidone (preparation given) was treated, at ≤15°, with a solution of allyl amine and Et3N in benzene, to give I (R1 = allyl, R2 = X = H, R3 = Et, R4 = CF3, Y = Z = O, n = 0) (II). Pre-emergence 4 lb II/acre totally controlled the broadleaf weeds and partially the grasses.

IT 127163-59-1P 127163-60-4P 127163-61-5P
127163-62-6P 127163-63-7P 127163-64-8P
127163-65-9P 127163-66-0P 127163-67-1P
127163-68-2P 127163-69-3P 127163-70-6P
127163-71-7P 127163-72-8P 127163-73-9P
127163-74-0P 127163-75-1P 127163-76-2P
127163-77-3P 127163-78-4P 127163-79-5P
127163-80-8P 127163-81-9P 127163-82-0P

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

127163-83-1P 127163-84-2P 127163-85-3P
127163-86-4P 127163-87-5P 127163-88-6P
127163-89-7P 127163-90-0P 127163-91-1P
127163-92-2P 127163-93-3P 127163-94-4P
127163-95-5P 127163-96-6P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide)

RN 127163-59-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-60-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-61-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-62-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(1-methylethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-63-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 3-chloro-4-ethyl-N-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-64-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N,N-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-68-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N,4-diethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-69-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-2-oxo-N-propyl-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-70-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(2-methylpropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-65-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-2-oxo-N-2-propenyl-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-66-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-butyl-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-67-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N,N-dibutyl-4-ethyl-2-oxo-1-[3-

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-71-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-[(2-chlorophenyl)methyl]-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-72-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-cyclopropyl-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 127163-73-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(2-methoxyethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-74-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-cyclopentyl-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-75-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-methoxy-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-76-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-methoxy-N-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-80-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-ethoxy-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-81-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-2-oxo-N-2-propynyl-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-82-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(4-fluorophenyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-77-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-cyclobutyl-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-78-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(2-methoxy-1-methylethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-79-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(2,2-dimethoxyethyl)-4-ethyl-2-oxo-1-[3-

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-83-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(3-chloro-2-propenyl)-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-84-2 HCAPLUS
CN Morpholine, 4-[[4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 127163-85-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(1-methylpropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-86-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(1-methylbutyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-87-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethenyl-N-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-88-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(2-hydroxyethyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-89-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-[2-(methylthio)ethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-90-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(3-methoxypropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-91-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-[3-(methylthio)propyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-92-2 HCAPLUS
CN Pyrrolidine, 1-[[4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 127163-93-3 HCAPLUS
CN Piperidine, 1-[[4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 127163-94-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-2-oxo-N-(1-phenylethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-95-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-ethyl-N-(2-hydroxypropyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 127163-96-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-(cyanomethyl)-4-ethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L5 · ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



10531573

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	108.00	281.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.60	-15.60

STN INTERNATIONAL LOGOFF AT 14:58:41 ON 16 MAR 2007